Because immunosuppression and hematologic malignancies are established risk factors for cSCC and ROR1 is known to be overexpressed in several hematologic neoplasms, we additionally assessed whether ROR1 expression was enriched in patients with hematologic malignancies. The gene discussed is ROR1; the disease is hematologic disorder.